Kornimate/medical-research-clean huggingface dataset:
multifocal contact lens use in previous contact lens wearers with near vision demands

Conditions: Presbyopia

Summary: the purpose of this study is to evaluate the use of a multifocal contact lens in people who previously wore contact lenses but discontinued due to age-related, near vision demands.


Eligibility criteria:
inclusion criteria: * has discontinued contact lens wear primarily due to age-related, near vision demands * requires a reading add of +0.50 to +1.75 d (inclusive) and is correctable to at least 6/9 monocular, distance and near with spectacle correction * has had an ocular examination in the last 2 years * other protocol-defined inclusion/exclusion criteria may apply exclusion criteria: * has any ocular disease * has more than a 2.00d prescription difference between eyes * cannot be fit successfully with the study contact lenses * has any systemic disease affecting ocular health * is using any systemic or topical medications that may affect ocular health * has undergone corneal refractive surgery * other protocol-defined inclusion/exclusion criteria may apply
t-cell minimal residual disease (mrd) evaluation using flow cytometric analysis

Conditions: Leukemia, Lymphocytic, Acute

Summary: to determine if mrd (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with all (acute lymphoblastic leukemia).


Eligibility criteria:
inclusion criteria: * children with newly diagnosed t-cell all
comparison of contoura vision outcomes programmed using the manifest refraction verses using phorcides planning software in patients with oblique astigmatism

Conditions: Myopia; Astigmatism

Summary: the objective is to compare the percentage of monocular udva -0.1 logmar (20/16) outcomes for each planning strategy (phorcides and manifest refraction) at the 3-month post operative visit.

this study is a randomized, prospective contralateral eye study of visual outcomes in eyes planned with phorcides compared to eyes planned using the manifest refraction after successful bilateral lasik surgery. subjects will be assessed pre-operatively, operatively and at 3 months postoperatively. clinical evaluations will include measurement of visual acuity, manifest refraction, and administration of a questionnaire.

Eligibility criteria:
inclusion criteria: * 18 years old and above * preoperative total corneal pachymetry 490um or above * bcva 20/20 or better * stable refractive error \<0.50d mrse change in preceding year * good general and ocular health * preoperative exam completed within three months of surgery * soft contact lens wear discontinued 3 days prior to preoperative exam and the procedure * residual stromal bed greater than 270um * candidates who qualify for contoura treatment ou (≤ -8.0 d sph and ≤ -3.0 d cyl) * candidates who elect to target both eyes targeted for emmetropia * ≤ -3.0 d oblique astigmatism as defined as an axis between 30-60 degrees or between 120-150 degrees exclusion criteria: * subjects with usual relative and absolute contraindications for lasik surgery (subjects with severe dry eye, subjects with recurrent corneal erosion, subjects with uncontrolled glaucoma, subjects with collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled diabetes, herpes, corneal dystrophies or degeneration; any irregular astigmatism) * pachymetry below 490 * autoimmune or immunodeficiency diseases, pregnant or nursing women * subjects with signs of inability to understand consent for study and procedure planned * subjects with history of previous ocular surgery the principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial. pregnancy has a known effect on the stability of refractions and visual acuity. as such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
pulsed electromagnetic field therapy for tmj dysfunction after facial penetrating injury

Conditions: TMJ Disorder

Summary: this study is aiming to investigate the effect of magnetic therapy in combination with traditional physical therapy on the pain and mouth opening, after facial penetrating wound injury with no facial fractures, that treated conservatively


Eligibility criteria:
inclusion criteria: * tmj pain and mouth opening limitation after 1 month of facial penetrating wound injury as the wound is fully healed. * tmj pain (in 1 or both joints) after facial penetrating wound injury. exclusion criteria: * patient excluded from the study if they had one of the following: * tmj fracture or dislocation * previous tmj surgeries * dental diseases * infectious or systemic diseases * pregnancy * malignancy * pacemaker or metal implants * systemic diseases that affect joint function such as rheumatoid arthritis.
safety study of nivolumab to treat advanced or metastatic non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: a study to evaluate the safety of nivolumab in participants with advanced or metastatic non-small cell lung cancer


Eligibility criteria:
inclusion criteria: * non small cell lung cancer (squamous or non-squamous) * at least one prior anti-cancer therapy that did not work * ecog performance scale 0-1 exclusion criteria: * cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by mri for 8 weeks after treatment is complete and within 28 days before first dose of study drug * active, known or suspected autoimmune disease or infection * prior immuno-oncology therapy * corticosteroids within 2 weeks of study drug administration other protocol defined inclusion/exclusion criteria could apply
prf for treating maxillary gingival recession

Conditions: Gingival Recession

Summary: this is a split-mouth, randomized, controlled clinical trial that aims to evaluate the clinical efficacy of platelet-rich fibrin (prf) membranes in conjunction with coronally advanced flap (caf) in treating maxillary gingival recession defects.


Eligibility criteria:
inclusion criteria: * greater than 18 years old * bilateral miller class i + ii recession in the upper jaw exclusion criteria: * smokers * patients with systemic diseases that could interfere with the healing * patients undergoing bisphosphonate therap .patients who previously received radiation therapy of the jaws.

Keywords: connective tissue graft prf membrane gingival recession
frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis

Conditions: Posterior Tibial Tendon Dysfunction; Pes Planus; Spondylitis, Ankylosing

Summary: this investigation aims to investigate the frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis.

posterior tibial tendon dysfunction is the most common cause of acquired pes planus deformity in healthy adults. the posterior tibial tendon stabilizes the hindfoot against valgus and eversion forces and acts as a support along the medial longitudinal arch. if the posterior tibial tendon loses its functionality, the other ligaments of the foot and the joint capsule gradually weaken as the height of the medial longitudinal arch decreases or disappears, and it develops with pes planus. the presence of pes planus and spondyloarthropathy are also risk factors for the development of posterior tibial tendon dysfunction. 100 participants aged between 20-70 years with ankylosing spondylitis were planned to be included in this investigation. posterior tibial tendon dysfunction frequency of patients with ankylosing spondylitis will be evaluated by both clinical examination and musculoskeletal ultrasonography device. the posterior tibial tendon will be evaluated by ultrasonography in terms of tendon diameter and fluid presence in 2 different locations in the retromalleolar area. bath ankylosing spondylitis disease activity index (basdai), bath ankylosing spondylitis functional index (basfi), ankylosing spondylitis quality of life (asqol) scale, functional reach test, timed up and go test, berg balance scale, dynamic and static balance with the sportkat device will be used as evaluation parameters. it was planned that the evaluations were made once.

Eligibility criteria:
inclusion criteria: * participitans who apply to the rheumatology outpatient clinic between the ages of 20-70 and who have been diagnosed with ankylosing spondylitis according to the modified newyork criteria will be included in this study. 1. ankylosing spondilitis exclusion criteria: 1. malignity 2. previous ankle surgery history 3. muscle disease 4. neuropsychiatric illnesses 5. i̇mbalance 6. visual problems 7. deafness

Keywords: posterior tibial tendon dysfunction ultrasonographic evaluation pes planus
optimising access to vocational rehabilitation for people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: people with multiple sclerosis (ms) often leave the workforce prematurely due to ms symptoms and difficulties managing workplace relationships and performance. vocational rehabilitation (vr) can improve job retention outcomes for people with ms, but there is a lack of evidence on the effectiveness of these interventions. a psychologist and occupational therapist-delivered vr intervention was previously developed to support people with ms to remain in paid employment. this programme was tested in a community setting and within the uk national health service (nhs). the preliminary findings demonstrate that the intervention is highly acceptable to people with ms and their employers and helped participants with ms to meet their vocational goals. however, the study also identified various barriers (e.g., lack of staff, service structure, etc.) to delivering this programme more widely within a healthcare setting. because of this, patient and public involvement (ppi) representatives suggested testing the vr intervention within the services provided by ms charities. this approach could be beneficial to reach people with ms who might be in the earlier stages of the illness and looking for information or who have not considered discussing "work" with their healthcare providers. therefore, the vr intervention msvr ("multiple sclerosis vocational rehabilitation") was adapted to be delivered by non-specialists working for ms charities. over recent years, the practice of training non-specialists to deliver evidence-based and complex interventions has increased to reach communities where there is a lack of resources or to help increase the reach of these interventions. this study aims to: 1. explore the feasibility and acceptability of providing employment support through ms charities. 2. determine the parameters for a future large-scale randomised controlled trial. 3. explore the experiences of those receiving and delivering the msvr intervention. sixty people with ms in paid employment will be recruited to receive support with employment tailored to their needs over six months. participants with ms will be asked to complete a booklet of questionnaires with variables known to affect employment status. approximately 20 participants will be asked to participate in a feedback interview at the end of the intervention.


Eligibility criteria:
inclusion criteria: 1. aged ≥18 2. can give informed consent, 3. can communicate in english, 4. are in paid employment (including self-employed). exclusion criteria: 1. planning to retire within the next 12 months. 2. currently receiving vocational rehabilitation support from the nhs or other employer services.

Keywords: vocational rehabilitation multiple sclerosis job retention
a study of suboptimally controlled participants previously taking injectable dmds for rms (click-ms)

Conditions: Multiple Sclerosis

Summary: to evaluate the effectiveness, patient-reported outcomes (pros) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (rms) including relapsing-remitting multiple sclerosis (rrms) and active secondary progressive multiple sclerosis (aspms),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (dmds) approved in the united states (us) for rms in a real-world setting.


Eligibility criteria:
inclusion criteria: * male or female participants greater than or equal to (\>=)18 years * signed informed consent * have diagnosis of rms including rrms and aspms and satisfy the approved indication for cladribine tablets as per united states prescribing information (uspi) * have time since diagnosis of rms of at least 12 months * had received their last previous injectable disease-modifying drug (dmd) for at least 3 months * have decided to initiate treatment with cladribine tablets during routine clinical care * meet criteria as per the approved uspi * have access to a valid e-mail address * in the opinion of the investigator, experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable dmd treatment exclusion criteria: * have been previously treated with cladribine in any dosing form * transitioning from previous injectable dmd solely for administrative reasons such as relocation * have comorbid conditions that preclude participation * have any clinical condition or medical history noted as contraindication on uspi * are currently participating in an interventional clinical trial * pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during the cladribine treatment period

Keywords: multiple sclerosis cladribine tablets observational mavenclad
plasma rich in growth factors (prgf) for the treatment of lichen sclerosus atrophicus of the vulva

Conditions: Lichen Sclerosus of Vulva

Summary: lichen sclerosus is a chronic dermatosis of the skin and semimucous membranes, characterized by the presence of well-defined atrophic white papules or plaques, which appear mainly on the skin of the anogenital region of both sexes, and less frequently on the skin of the trunk. , mainly affecting postmenopausal women. there is no absolutely effective treatment. only potent topical corticosteroids control symptoms and improve outcomes, although prolonged use can increase skin atrophy. in severe vulvar lesions, 0.05% clobetasol propionate is indicated, followed by a less potent topical corticosteroid. relapses often occur if treatment is discontinued altogether, but respond well to reintroduction of treatment. plasma rich in growth factors (prgf®) is a mixture of autologous proteins, prepared from a certain volume of platelet-rich plasma obtained from a small volume of blood, which does not contain leukocytes. to date, there have been no studies evaluating prgf® treatment in vulvar lichen sclerosus. however, there are several publications that assess the efficacy of prps as a treatment for vulvar lichen sclerosus. this clinical study has been designed with the aim of evaluating the efficacy of prgf® in reducing the main symptoms of vaginal lichen sclerosus atrophicus.


Eligibility criteria:
inclusion criteria: * age \>18 years * woman with symptoms associated with lea confirmed by histological study * being 1 month without prior treatment in the affected area as a washing period * availability of observation during the treatment period * signature of the informed consent exclusion criteria: * acute somatic disease * infection in the intervention area or active systemic infection * history of cancerous or precancerous lesions in the intervention area * in active treatment with other local treatments in the intervention area * under active treatment with immunosuppressants and/or anticoagulants * history of allergies to blood derivatives * previous diagnosis of coagulopathies * regular and continuous treatment with nsaids * positive markers for hcv, afhbs, hiv-i/ii or pt * pregnancy or women of childbearing age not taking contraceptive measures * lactating women * treatment with monoclonal antibodies * liver failure * any inability to participate in the study
effect of proton pump inhibitor of daily use for one month on kidney function test

Conditions: Proton Pump Inhibitor Allergy

Summary: the aim of this study to: evaluate the association between prolonged use of ppi and adverse renal outcomes on patients with normal renal function and others with abnormal renal function

proton pump inhibitors (ppis) are one of the most widely used classes of drugs and are prescribed primarily for gastric acid-related diseases, eradication of helicobacter pylori, and prevention of nonsteroidal anti-inflammatory drug (nsaid)-induced gastropathy,and gastroesophagial reflux diseases , although ppis have an excellent overall safety profile, some severe adverse effects, which include bone fracture, dementia, myocardial infarction, infections, micronutrient deficiencies, and kidney diseases, ppis may trigger acute interstitial nephritis,a potentially sever adverse event commonly associated with acute kidney injury. the increase in prescription and inadequate use of this class of medication calls for studies on the effects of prolonged ppi therapy on renal function.

Eligibility criteria:
inclusion criteria: * patients with peptic ulcer disease or gastroesophagial reflux with normal l renal function * patients with peptic ulcer disease or gastroeosophagial reflux with abnormal renal function exclusion criteria: * 1- cigarette smoker: cigarette smoking status was defined categorically as current,former, or never smoker at baseline. 2-biabetic patients: diabetes mellitus is defined by a fasting blood glucose concentration \>_ 126 mg/dl ,random glucose level of \>200 mg 3-patients take corticosteroid 4-patients with hypersensitivity to these drugs
ga-68-psma-11 in men with prostate cancer

Conditions: Prostate Cancer; Prostate Adenocarcinoma

Summary: the purpose of this study is to provide access to ga-68-psma-11 pet for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer. all patients will receive conventional imaging (mri, ct, and/or a molecular imaging bone scan) as well as ga-68-psma-11 pet in order to evaluate the utility of diagnostic testing in patients with positive psa status, a comparison of results from conventional imaging and psma pet imagining will be performed.

participants (male veterans) with initial diagnosis of prostate cancer or biochemically recurrent disease that consent to participate in the study will receive both conventional imaging (mri, ct, and/or molecular imaging bone scan) as well as ga-68-psma-11 pet/ct. following baseline assessment (visit #1), ga-68-psma-11 (3-7 mci) will be administered as a single intravenous administration with pet/ct performed approximately 60 minutes after injection (visit #2a). at approximately 120 minutes after injection of ga-68-psma-11, the final evaluation for safety and tolerability will occur (visit #2b)

Eligibility criteria:
inclusion criteria: * able to tolerate pet/ct imaging and one or more of the following: * patients with newly diagnosed prostate cancer with primary staging classified at high/intermediate risk per nccn guidelines or * biochemical recurrence: patients with rising psa after definitive therapy with prostatectomy or radiation therapy or other local therapies exclusion criteria: * claustrophobia or any other condition that would preclude pet/ct imaging. * any constellation of medical conditions that indicate expectancy of less than one year

Keywords: psma biochemically recurrent prostate cancer
retrospective acute care appendectomy study

Conditions: Acute Appendicitis

Summary: the purpose of this retrospective study is to compare perioperative data for subjects who have undergone an emergent or urgent robotic-assisted or laparoscopic appendectomy for acute appendicitis.


Eligibility criteria:
inclusion criteria: * subject is 22 years of age or older at time of procedure * subject has undergone robotic-assisted or laparoscopic emergent or urgent appendectomy for acute appendicitis between 2018 and 30 days prior to irb approval exclusion criteria: * subject with appendiceal neoplasms * subject who underwent a single-port appendectomy * subject who was pregnant or breastfeeding at the time of the procedure

Keywords: appendectomy robotic-assisted acute care laparoscopic
rfa to prevent metachronous squamous neoplasia recurrence after complete endoscopic submucosal dissection

Conditions: Esophageal Squamous Cell Neoplasm

Summary: esophageal cancer is a highly lethal disease, and its incidence is still increasing in the world. recent advances in image-enhanced techniques such as lugol chromoendoscopy and narrow band imaging, the number of patients with early esophageal squamous cell neoplasias (escns) detected has markedly increased. endoscopic submucosal dissection (esd) enables en bloc resection of the neoplasia, and the resected specimen allows for a pathological assessment to evaluate the curability. however, the patients who received complete esd for early escns frequently developed metachronous recurrence. the cumulative metachronous recurrence rate at 5 years was 50%, and the mean annual incidence of newly diagnosed metachronous tumors was 10%. among them, those with "speckled" lugol staining pattern over the esophageal background mucosa have the highest risk and should be seen as a precancerous lesion of esccs. this issue is gaining attention in the era of endoscopic treatment, but currently there was no appropriate strategy to prevent the tumor recurrence in these high-risk subjects. endoscopic radiofrequency ablation (rfa) is a rapidly evolving therapeutic modality, and recent studies have shown its efficacy and safety for eradicating for flat type early escns. to search a best strategy for the prevention of escns, the investigators thus propose a hypothesis that the preemptive rfa for esophageal "speckled" lugol background mucosa may prevent the metachronous neoplastic recurrence after complete endoscopic resection.


Eligibility criteria:
inclusion criteria: * adults with early stage escns (squamous high grade dysplasia, carcinoma in situ, or t1n0m0 scc) who were treated by endoscopic submucosal dissection. * lugol staining showed "speckled" (\>10 small lugol-unstained lesions) pattern of background mucosa. exclusion criteria: * having a history of incomplete endoscopic treatment, or complications during/after treatment (perforation, stricture). * having history of systemic chemotherapy or radiation therapy for esophagus or post esophagectomy. * life expectancy \<2 yr. * decompensated cirrhosis (child score b, c). * having large esophageal varices. * poor performance status (ecog\>2).

Keywords: early esophageal squamous cell neoplasm radiofrequency ablation endoscopic submucosal dissection esophageal cancer recurrence field cancerization
faslodex in mccune-albright syndrome

Conditions: Puberty, Precocious; McCune-Albright Syndrome

Summary: the purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called faslodex (fulvestrant) in the treatment of progressive precocious puberty (ppp) (early puberty) in girls with mccune-albright syndrome (mas)


Eligibility criteria:
inclusion criteria: * females less than or equal to 10 years of age (prior to 11th birthday) * diagnosis of mas * ppp associated with mas exclusion criteria: * received any prior treatment for ppp associated with mas with fulvestrant * abnormal platelet count or liver function tests * bleeding disorders * long term anticoagulation therapy * known hypersensitivity to any component of the study drug

Keywords: progressive precocious puberty ppp mccune-albright syndrome mas